Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Covington
Federal Trade Commission
Accenture
Harvard Business School
Daiichi Sankyo
Johnson and Johnson
Baxter

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRIVARACETAM

« Back to Dashboard

Clinical Trials for Brivaracetam

Trial ID Title Status Sponsor Phase Summary
NCT00150800 This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment Active, not recruiting UCB PHARMA Inc. (US) Phase 3 This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.
NCT00160667 A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Completed UCB Pharma Phase 2 Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.
NCT00175825 A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. Completed UCB Pharma Phase 2 This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
NCT00175916 Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy Active, not recruiting UCB Pharma Phase 3 This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).
NCT00175929 A Study of Brivaracetam in Subjects With Partial Onset Seizures Completed UCB Pharma Phase 2 This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
NCT00357669 Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults Completed UCB Pharma SA Phase 3 The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.
NCT00368251 Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults Completed UCB Pharma Phase 3 The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Brivaracetam

Condition Name

Condition Name for Brivaracetam
Intervention Trials
Epilepsy 23
Partial Seizures With or Without Secondary Generalization 2
Healthy Volunteers 2
Unverricht-Lundborg Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Brivaracetam
Intervention Trials
Epilepsy 24
Seizures 12
Unverricht-Lundborg Syndrome 2
Neoplasm Metastasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Brivaracetam

Trials by Country

Trials by Country for Brivaracetam
Location Trials
United States 254
Canada 24
Germany 15
France 14
Spain 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Brivaracetam
Location Trials
Texas 14
Ohio 14
New York 14
Virginia 11
Kentucky 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Brivaracetam

Clinical Trial Phase

Clinical Trial Phase for Brivaracetam
Clinical Trial Phase Trials
Phase 3 18
Phase 2/Phase 3 2
Phase 2 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Brivaracetam
Clinical Trial Phase Trials
Completed 18
Active, not recruiting 4
Terminated 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Brivaracetam

Sponsor Name

Sponsor Name for Brivaracetam
Sponsor Trials
UCB Pharma 16
UCB Biopharma S.P.R.L. 7
UCB Pharma SA 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Brivaracetam
Sponsor Trials
Industry 35
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Colorcon
Daiichi Sankyo
Argus Health
US Department of Justice
US Army
Cipla
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.